Systemic Treatments of Castration-Resistant Prostate Cancer.
Urol Clin North Am 2026 May; 53(2):317-330.UC

Abstract

Patients can develop metastatic castrate resistant prostate cancer either by developing resistance to hormone therapies after presenting with metastatic disease at diagnosis or developing metastatic disease after all curative intent and hormonal therapies in non-metastatic setting.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Desai ANDepartment of Hematology/Oncology, Maimonides Health, Maimonides Medical Center, Brooklyn, NY, USA. Electronic address: and103@rwjms.rutgers.edu.

Fleyshman MDepartment of Hematology/Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.

Lall NDepartment of Hematology/Oncology, Maimonides Health, Maimonides Medical Center, Brooklyn, NY, USA.

Saraiya BDepartment of Hematology/Oncology, Maimonides Health, Maimonides Medical Center, Brooklyn, NY, USA; Division of Medical Oncology and Section of Solid Tumor, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

MeSH

HumansMaleProstatic Neoplasms, Castration-ResistantAndrogen Antagonists

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

41986026

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.